CL2017000335A1 - Tratamientos conjuntos con anticuerpos anti cd40 - Google Patents

Tratamientos conjuntos con anticuerpos anti cd40

Info

Publication number
CL2017000335A1
CL2017000335A1 CL2017000335A CL2017000335A CL2017000335A1 CL 2017000335 A1 CL2017000335 A1 CL 2017000335A1 CL 2017000335 A CL2017000335 A CL 2017000335A CL 2017000335 A CL2017000335 A CL 2017000335A CL 2017000335 A1 CL2017000335 A1 CL 2017000335A1
Authority
CL
Chile
Prior art keywords
treatments
antibodies
joint
joint treatments
antigen
Prior art date
Application number
CL2017000335A
Other languages
English (en)
Spanish (es)
Inventor
Peter Ellmark
Per Norlen
Niina Veitonmäki
Original Assignee
Alligator Bioscience Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53836090&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2017000335(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB1414270.7A external-priority patent/GB201414270D0/en
Priority claimed from GBGB1507541.9A external-priority patent/GB201507541D0/en
Application filed by Alligator Bioscience Ab filed Critical Alligator Bioscience Ab
Publication of CL2017000335A1 publication Critical patent/CL2017000335A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CL2017000335A 2014-08-12 2017-02-09 Tratamientos conjuntos con anticuerpos anti cd40 CL2017000335A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1414270.7A GB201414270D0 (en) 2014-08-12 2014-08-12 Antibodies
GB201422614 2014-12-18
GBGB1507541.9A GB201507541D0 (en) 2015-05-01 2015-05-01 Antibodies

Publications (1)

Publication Number Publication Date
CL2017000335A1 true CL2017000335A1 (es) 2017-08-11

Family

ID=53836090

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017000335A CL2017000335A1 (es) 2014-08-12 2017-02-09 Tratamientos conjuntos con anticuerpos anti cd40

Country Status (25)

Country Link
US (3) US11149090B2 (enExample)
EP (3) EP3552665A3 (enExample)
JP (1) JP6654187B2 (enExample)
KR (1) KR102443258B1 (enExample)
CN (3) CN114099671A (enExample)
AU (1) AU2015303164B2 (enExample)
CA (1) CA2957146A1 (enExample)
CL (1) CL2017000335A1 (enExample)
CO (1) CO2017001317A2 (enExample)
CR (1) CR20170096A (enExample)
DK (1) DK3180087T3 (enExample)
EA (1) EA201790339A1 (enExample)
EC (1) ECSP17008984A (enExample)
ES (1) ES2725463T3 (enExample)
IL (1) IL250512B (enExample)
MA (1) MA47472A (enExample)
MX (1) MX382549B (enExample)
NI (1) NI201700015A (enExample)
PE (1) PE20170680A1 (enExample)
PH (1) PH12017500229A1 (enExample)
SG (1) SG11201701070WA (enExample)
SV (1) SV2017005380A (enExample)
UA (1) UA119783C2 (enExample)
WO (1) WO2016023960A1 (enExample)
ZA (1) ZA201701126B (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX339239B (es) 2011-04-29 2016-05-18 Apexigen Inc Anticuerpos anti-cd40 y metodos de uso.
DK2953634T3 (da) 2013-02-07 2021-08-30 Massachusetts Gen Hospital Fremgangsmåder til udvidelse eller udtømning af regulerende t-celler
AR097584A1 (es) 2013-09-12 2016-03-23 Hoffmann La Roche Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano
AU2014361473B2 (en) 2013-12-12 2019-09-26 Jiangsu Hengrui Medicine Co., Ltd. PD-1 antibody, antigen-binding fragment thereof, and medical application thereof
HRP20231392T1 (hr) 2015-05-15 2024-04-26 The General Hospital Corporation Antagonistička protutijela na superobitelj receptora za faktor tumorske nekroze
US20190135929A1 (en) 2015-08-28 2019-05-09 The General Hospital Corporation Agonistic anti-tumor necrosis factor receptor 2 antibodies
TW202216787A (zh) 2015-11-18 2022-05-01 美商默沙東藥廠 Pd1及／或 lag3結合劑
MA44082A (fr) 2015-12-14 2018-10-24 Macrogenics Inc Molécules bispécifiques présentant une immunoréactivité par rapport à pd-1 et à ctla-4 et leurs procédés d'utilisation
EP3455262A4 (en) * 2016-05-13 2020-04-08 The General Hospital Corporation ANTAGONISTIC ANTI-TUMOR NECROSE FACTOR RECEPTOR SUPER FAMILY ANTIBODIES
RU2769282C2 (ru) 2016-06-20 2022-03-30 Кимаб Лимитед Анти-PD-L1 и IL-2 цитокины
EA201990293A1 (ru) 2016-07-14 2019-07-31 Генмаб А/С Мультиспецифичные антитела против cd40 и cd137
JP7138094B2 (ja) 2016-08-25 2022-09-15 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト マクロファージ活性化剤と組み合わせた抗ｃｓｆ－１ｒ抗体の間欠投与
EP3532505A4 (en) 2016-10-25 2019-12-25 Urogen Pharma Ltd. BODY CAVES IMMUNODULATING TREATMENTS
EP3534951A4 (en) * 2016-11-02 2020-09-23 Apexigen, Inc. ANTI-CD40 ANTIBODIES IN COMBINATION AND METHOD OF USES
JP7304287B2 (ja) 2016-12-22 2023-07-06 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 抗ｐｄ－ｌ１／ｐｄ１治療の不成功後の、抗ｐｄ－ｌ１抗体との組み合わせでの抗ｃｓｆ－１ｒ抗体を用いた腫瘍の治療
EP3569616B1 (en) * 2017-01-13 2021-09-29 Taizhou Hanzhong Biopharmaceutics, Inc. Monoclonal antibody against pd-1 and applications thereof
JP2020510673A (ja) * 2017-03-03 2020-04-09 ヤンセン バイオテツク，インコーポレーテツド がんの治療のための低分子ｃｓｆ−１ｒ阻害剤とｃｄ４０に特異的に結合するアゴニスト抗体とを含む併用療法
CA3071217A1 (en) 2017-08-31 2019-03-07 Multimmune Gmbh Hsp70 based combination therapy
BR112020018761A2 (pt) * 2018-03-13 2020-12-29 Hibercell, Inc. Imunoterapia combinada com beta-glucano e agonista de cd40
EP3807320A4 (en) * 2018-06-12 2022-03-23 BioNTech US Inc. POLYTHERAPY INCLUDING A VACCINE BASED ON NEO ANTIGENS
JP2021528393A (ja) 2018-06-15 2021-10-21 フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド 後細胞シグナル伝達因子の調節による免疫活性の上昇
JP7155403B2 (ja) * 2018-08-20 2022-10-18 ファイザー・インク 抗ｇｄｆ１５抗体、組成物および使用の方法
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
WO2020102739A1 (en) 2018-11-15 2020-05-22 The General Hospital Corporation Agonistic tumor necrosis factor receptor superfamily polypeptides
AU2019383548A1 (en) 2018-11-23 2021-06-24 Strike Pharma Ab Bi-specific conjugates
EP3892634A4 (en) * 2018-11-30 2022-11-16 Jiangsu Hengrui Pharmaceuticals Co., Ltd. ANTI-CD40 ANTIBODIES, ANTIGEN BINDING FRAGMENT AND PHARMACEUTICAL USE THEREOF
EP3962493A2 (en) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V, Inc. Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor
US20230174658A1 (en) * 2019-05-28 2023-06-08 Janssen Biotech, Inc. Method of providing safe administration of an anti-cd40 antibody
US20220370418A1 (en) 2019-09-09 2022-11-24 Basilea Pharmaceutica International AG Pharmaceutical combinations comprising a furazanobenzimidazoles and a cd40 agonist for use in the treatment of neoplastic diseases
US20230114107A1 (en) 2019-12-17 2023-04-13 Flagship Pioneering Innovations V, Inc. Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
US20230055235A1 (en) * 2019-12-27 2023-02-23 Interoligo Corporation. Anti-cancer immunotherapeutic composition for treating cancer
GB202008003D0 (en) 2020-05-28 2020-07-15 Quine Medical Ab Anti-CD40 antibody
WO2022006179A1 (en) 2020-06-29 2022-01-06 Flagship Pioneering Innovations V, Inc. Viruses engineered to promote thanotransmission and their use in treating cancer
WO2022002065A1 (zh) * 2020-06-30 2022-01-06 百奥泰生物制药股份有限公司 抗cd40抗体或抗原结合片段及其应用
WO2022036495A1 (en) 2020-08-17 2022-02-24 Utc Therapeutics Inc. Lymphocytes-antigen presenting cells co-stimulators and uses thereof
EP4313109A1 (en) 2021-03-31 2024-02-07 Flagship Pioneering Innovations V, Inc. Thanotransmission polypeptides and their use in treating cancer
CA3224374A1 (en) 2021-06-29 2023-01-05 Flagship Pioneering Innovations V, Inc. Immune cells engineered to promote thanotransmission and uses thereof
EP4415757A4 (en) * 2021-10-15 2025-10-08 Univ Rockefeller COMBINATION OF ANTI-CD40 ANTIBODIES AND IL-15 FOR THE TREATMENT OF CANCER
CN118201636A (zh) * 2021-10-26 2024-06-14 萨摩亚商柏沛生医股份有限公司 抗癌症及感染性疾病的组合疗法
WO2023247050A1 (en) 2022-06-23 2023-12-28 Alligator Bioscience Ab Combination therapies
EP4598946A1 (en) 2022-10-05 2025-08-13 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
WO2024151687A1 (en) 2023-01-09 2024-07-18 Flagship Pioneering Innovations V, Inc. Genetic switches and their use in treating cancer

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
SE459005B (sv) 1985-07-12 1989-05-29 Aake Rikard Lindahl Saett att framstaella sfaeriska polymerpartiklar
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
WO1992022653A1 (en) 1991-06-14 1992-12-23 Genentech, Inc. Method for making humanized antibodies
WO1996006641A1 (en) 1994-08-29 1996-03-07 Prizm Pharmaceuticals, Inc. Conjugates of vascular endothelial growth factor with targeted agents
CA2192782C (en) 1995-12-15 2008-10-14 Nobuyuki Takechi Production of microspheres
US6051228A (en) 1998-02-19 2000-04-18 Bristol-Myers Squibb Co. Antibodies against human CD40
WO2001083755A2 (en) 2000-04-28 2001-11-08 La Jolla Institute For Allergy And Immunology Human anti-cd40 antibodies and methods of making and using same
ATE295882T1 (de) 2000-12-12 2005-06-15 Alligator Bioscience Ab Eine methode zur in vitro molekularen evolution der proteinfunktion
ATE374214T1 (de) 2001-04-27 2007-10-15 Kirin Brewery Monoklonaler anti-cd-40-antikörper
CN1671416B (zh) 2001-07-12 2013-01-02 杰斐逊·富特 超人源化抗体
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
US7432063B2 (en) 2002-02-14 2008-10-07 Kalobios Pharmaceuticals, Inc. Methods for affinity maturation
US20040110226A1 (en) 2002-03-01 2004-06-10 Xencor Antibody optimization
ES2285118T5 (es) 2002-05-17 2012-09-21 Alligator Bioscience Ab Un método para el desarrollo molecular in vitro de una función proteica.
CN101001872A (zh) * 2004-04-16 2007-07-18 宏观基因有限公司 FcγRIIB－特异性抗体及其使用方法
CA2564296A1 (en) 2004-04-27 2006-07-13 Novartis Vaccines And Diagnostics, Inc. Antagonist anti-cd40 monoclonal antibodies and methods for their use
AU2006244885B2 (en) 2005-05-09 2011-03-31 E. R. Squibb & Sons, L.L.C. Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
ATE485057T1 (de) 2005-05-26 2010-11-15 Seattle Genetics Inc Humanisierte antikörper gegen cd40 und verfahren zu ihrer anwendung
GB0620894D0 (en) * 2006-10-20 2006-11-29 Univ Southampton Human immune therapies using a CD27 agonist alone or in combination with other immune modulators
AU2009206506B2 (en) 2008-01-23 2013-01-10 Xencor, Inc. Optimized CD40 antibodies and methods of using the same
AU2009286247A1 (en) * 2008-08-29 2010-03-04 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Delivery of a CD40 agonist to a tumor draining lymph node of a subject
ES2581516T3 (es) * 2009-09-16 2016-09-06 The Chemours Company Fc, Llc Aparato enfriador que contiene trans-1,1,1,4,4,4-hexafluoro-2-buteno y procedimientos para producir enfriamiento en él
GB201006096D0 (en) 2010-04-13 2010-05-26 Alligator Bioscience Ab Novel compositions and uses thereof
JP6238459B2 (ja) 2011-08-01 2017-11-29 ジェネンテック， インコーポレイテッド Ｐｄ−１軸結合アンタゴニストとｍｅｋ阻害剤を使用する癌の治療方法
GB201115280D0 (en) 2011-09-05 2011-10-19 Alligator Bioscience Ab Antibodies, uses and methods
AR090263A1 (es) 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
EP2951209A4 (en) 2013-01-31 2016-06-22 Univ Jefferson CD40 OX40 AGONIST FUSION PROTEIN AND USES THEREOF
EA201600474A1 (ru) 2013-12-20 2016-11-30 Ф. Хоффманн-Ля Рош Аг Комбинированная терапия с использованием антитела к ang2 и агониста cd40
TWI693232B (zh) 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
MA53243A (fr) 2015-04-17 2021-06-23 Bristol Myers Squibb Co Compositions comprenant une combinaison de ipilimumab et nivolumab
CN107810198B (zh) 2015-05-29 2021-09-03 艾伯维公司 抗cd40抗体及其用途
CN107771184B (zh) 2015-06-29 2022-11-01 百时美施贵宝公司 针对cd40的抗体
CA2990015A1 (en) 2015-06-29 2017-01-05 The Rockefeller University Antibodies to cd40 with enhanced agonist activity

Also Published As

Publication number Publication date
US11149090B2 (en) 2021-10-19
UA119783C2 (uk) 2019-08-12
BR112017002729A2 (pt) 2018-02-27
JP2017524715A (ja) 2017-08-31
WO2016023960A1 (en) 2016-02-18
KR102443258B1 (ko) 2022-09-14
AU2015303164A1 (en) 2017-03-09
ECSP17008984A (es) 2017-05-31
MX382549B (es) 2025-03-13
AU2015303164B2 (en) 2020-10-29
CR20170096A (es) 2017-06-15
MX2017001864A (es) 2017-08-02
CN114099671A (zh) 2022-03-01
MA47472A (fr) 2019-12-18
IL250512A0 (en) 2017-03-30
DK3180087T3 (da) 2019-05-13
EP3552665A3 (en) 2019-12-18
NZ729270A (en) 2024-03-22
KR20170041790A (ko) 2017-04-17
EP3180087A1 (en) 2017-06-21
SV2017005380A (es) 2018-09-14
US20240132609A1 (en) 2024-04-25
US20240228643A9 (en) 2024-07-11
EP4653463A2 (en) 2025-11-26
EP3552665A2 (en) 2019-10-16
IL250512B (en) 2021-08-31
PE20170680A1 (es) 2017-06-14
CN106573981A (zh) 2017-04-19
CO2017001317A2 (es) 2017-08-10
SG11201701070WA (en) 2017-03-30
NI201700015A (es) 2017-05-12
EP3180087B1 (en) 2019-03-13
CN119280407A (zh) 2025-01-10
US20210403589A1 (en) 2021-12-30
ZA201701126B (en) 2025-08-27
CA2957146A1 (en) 2016-02-18
ES2725463T3 (es) 2019-09-24
PH12017500229A1 (en) 2017-07-10
US20170226217A1 (en) 2017-08-10
JP6654187B2 (ja) 2020-02-26
EA201790339A1 (ru) 2017-06-30

Similar Documents

Publication Publication Date Title
CL2017000335A1 (es) Tratamientos conjuntos con anticuerpos anti cd40
EA201990296A1 (ru) Антитела против siglec-7 для лечения рака
MX2021008053A (es) Metodos para monitorear y terapias para usarse en tratar el cancer.
CL2017000285A1 (es) Terapia combinada para el tratamiento de un paramixovirus
CO2018000809A2 (es) Anticuerpos para cd40
ECSP17005649A (es) Anticuerpos anti-tau humanizados
CO2017000571A2 (es) Procedimiento de inactivación de inmunoglobulina endógena que permite facilitar procedimientos médicos que se ven afectados por la presencia de inmunoglobulina endógena
MX2017005258A (es) Terapia combinada para tratamiento de enfermedad.
BR112016005816A2 (pt) Combinação de anticorpos anti-lag-3 e anticorpos anti-pd-1 para tratar tumores
BR112018014016A2 (pt) combinação de um agonista de ox40 e um agonista de anticorpo monoclonal 4-1bb para tratamento de câncer
CL2017000558A1 (es) Terapia de combinación
MX2016002826A (es) Anticuerpos anti-b7-h1 para tratar tumores.
MX2016015363A (es) Terapias de combinacion para el tratamiento de cancer.
EA201791736A1 (ru) Комбинированная терапия для лечения рака
MX2016014189A (es) Anticuerpos anti ligando 1 de muerte programada (b7-h1) y anti antigeno 4 de linfocito t citotoxico (anti-ctla-4) para tratar el cancer de pulmon no microcitico.
MX2018012493A (es) Métodos para controlar y tratar el cáncer.
BR112015030356A2 (pt) métodos de tratamento de uma taupatia
CL2017002983A1 (es) Terapia combinada de un anticuerpo anti-cd-20 con un inhibidor de bcl-2 y un inhibidor de mdm2
BR112018013733A2 (pt) combinações anti-cd20 para o tratamento de tumores a
MX387283B (es) Tratamiento del cancer con tg02.
MX2021011334A (es) Anticuerpos que tienen especificidad para btn2 y usos de los mismos.
UA97456U (en) METHOD FOR THE TREATMENT OF PATIENTS WITH CERVICAL CANCER of II-III stage
EA201691907A1 (ru) Комбинированная терапия кураксинами